Actinogen Medical Ltd. has announced that its independent Data Monitoring Committee has recommended the continuation of the XanaMIA pivotal Alzheimer's disease trial following a positive interim analysis of unblinded safety and efficacy data. The trial is fully enrolled, and topline final results are expected to be reported in November 2026. Following the completion of the trial, results will be presented at a key Alzheimer's disease scientific meeting and published in a peer-reviewed journal. All participants in the XanaMIA trial are eligible for an open-label extension phase, during which they will receive Xanamem 10 mg for up to 25 months. Additionally, a second and larger global pivotal trial is planned to commence in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinogen Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646961-en) on February 02, 2026, and is solely responsible for the information contained therein.